These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database. Tang Q, Han Y, Song M, Peng J, Zhang M, Ren X, Sun H. Medicine (Baltimore); 2024 Mar 29; 103(13):e37587. PubMed ID: 38552079 [Abstract] [Full Text] [Related]
48. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report. Miyauchi Y, Naito H, Tsunemori H, Tani R, Hasui Y, Miyake Y, Minamino T, Ishikawa R, Kushida Y, Haba R, Sugimoto M. J Med Case Rep; 2021 Oct 15; 15(1):508. PubMed ID: 34649593 [Abstract] [Full Text] [Related]
50. Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma. Takahashi M, Takishita M, Yamazato Y, Kakinoki H, Udo K, Tobu S, Noguchi M. CEN Case Rep; 2023 May 15; 12(2):237-241. PubMed ID: 36402939 [Abstract] [Full Text] [Related]
51. Fulminant Type 1 Diabetes Mellitus Caused by Long-Term Nivolumab Administration Followed by Nivolumab plus Cabozantinib Combination. Homma T, Yoshida N, Tanaka K, Isemura M, Torii S, Kinoshita T, Esaki H, Sakakibara T, Takimoto N. Chemotherapy; 2023 May 15; 68(1):44-47. PubMed ID: 36327909 [Abstract] [Full Text] [Related]
53. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report. Pesola G, Murianni V, Rebuzzi SE, Banna GL, Cerbone L, Catalano F, Borea R, Gandini A, Cremante M, Puglisi S, Trovato F, Fornarini G. Immunotherapy; 2021 Dec 15; 13(17):1379-1386. PubMed ID: 34743545 [Abstract] [Full Text] [Related]
54. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature. Newman C, Kgosidalwa O, Hakami OA, Kennedy C, Grogan L, Agha A. BMC Endocr Disord; 2021 Feb 27; 21(1):33. PubMed ID: 33639911 [Abstract] [Full Text] [Related]
58. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Hasegawa S, Ikesue H, Nakao S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Inoue M, Satake R, Yoshida Y, Goto F, Hashida T, Nakamura M. Pharmacoepidemiol Drug Saf; 2020 Oct 27; 29(10):1279-1294. PubMed ID: 32869941 [Abstract] [Full Text] [Related]
60. A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab. Kidawara Y, Kadoya M, Kakutani-Hatayama M, Koyama H. Case Rep Endocrinol; 2024 Oct 27; 2024():4662803. PubMed ID: 38559614 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]